Quick Facts: Uses of Inflamac retard

• Support for joint discomfort: May offer relief for stiffness and pain associated with chronic joint conditions.
• Helps manage inflammation: Intended to address swelling and other symptoms linked to inflammatory states.
• Relief for certain pain: Used in managing specific instances of mild to moderate discomfort.

---

What Inflamac retard treats: main uses and benefits

Inflamac retard is a medication option prescribed by healthcare professionals to help support patient comfort by addressing symptoms related to various inflammatory conditions. Its primary use is in the management of signs associated with certain types of arthritis, including osteoarthritis and rheumatoid arthritis. In these contexts, the medication is intended to assist in relieving joint stiffness and reducing swelling to improve general well-being.

Additionally, Inflamac retard may be utilized to manage discomfort in specific situations, such as ankylosing spondylitis (a condition affecting the spine's joints) and in the relief of mild to moderate acute pain. This formulation is designed to contribute to a therapeutic regimen that aims to support symptom resolution within a reasonable timeframe, as determined by a physician.

Official Eligibility Profile for Inflamac retard

Inflamac retard (Diclofenac prolonged-release) eligibility is defined by official regulatory documents, strictly outlining who can use the medication and who is formally prohibited.

Absolute Contraindications

Use is prohibited in patients with a history of hypersensitivity to Diclofenac or any NSAID, including those with aspirin-sensitive asthma. It is also contraindicated in the presence of active gastrointestinal ulceration, bleeding, or perforation, and in the setting of severe cardiac, hepatic, or renal failure. The medicine must not be used during the last trimester of pregnancy (from 30 weeks gestation) or for peri-operative pain following Coronary Artery Bypass Graft (CABG) surgery.

Population and Conditional Restrictions

Age/Condition	Regulatory Status
Children/Adolescents	Not suitable or not recommended due to the prolonged-release strength and lack of established data.
Elderly Patients	Use requires caution; the lowest effective dose should be considered, especially for frail patients.
Mild Organ Impairment	Use requires caution and close monitoring in patients with mild to moderate renal or hepatic impairment.
Pregnancy (20–30 weeks)	Use must be limited and only if clearly necessary.

Eligibility is generally established for adults (18 years and older) who do not possess any of the specified contraindications or limiting conditions.

Inflamac retard (Diclofenac sodium) has officially documented interaction profiles, resulting in specific regulatory restrictions and monitoring requirements when used with other products. Formal contraindications strictly prohibit its use in the third trimester of pregnancy and for the treatment of peri-operative pain associated with coronary artery bypass graft (CABG) surgery. Due to the risk of additive adverse effects, co-administration with other systemic Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors, must be avoided.

Several interactions affect systemic drug concentrations. Co-administration is officially documented to increase the blood concentrations of Lithium and the serum concentration and half-life of Digoxin, requiring regulatory attention. Serious interactions have also been reported when the product is used with high-dose Methotrexate.

Other interactions relate to pharmacodynamic risk. Using Inflamac retard alongside Anticoagulants (such as Warfarin), Systemic Corticosteroids, or SSRIs/SNRIs significantly raises the officially documented risk of serious gastrointestinal bleeding. Furthermore, the product may diminish the intended effects of medicines used for blood pressure control, including ACE Inhibitors, ARBs, and Diuretics. Regulatory documents specify that this latter interaction carries a heightened risk of renal function deterioration when these combinations are used in the elderly or those with existing renal impairment. Finally, the regulatory labeling explicitly classifies the consumption of Alcohol during use as unsafe.

Inhibition of the Prostaglandin Synthesis Pathway

The mechanism of Inflamac retard's active ingredient, Diclofenac, involves its function as a reversible inhibitor of Cyclooxygenase (COX) enzymes, particularly the inducible COX-2 isoform. This interaction occurs at the enzyme's active site, blocking its ability to convert arachidonic acid into prostaglandin precursors. The resulting decrease in prostaglandin concentration initiates the downstream modulation of several physiological processes.

This molecular block reduces the chemical signaling that drives both peripheral nociceptor sensitization and local vascular permeability associated with inflammatory responses. The reduction in central prostaglandins in the hypothalamus results in the modulation of the body's thermoregulatory set-point.

Mechanism for Sustained Local Target Engagement

The prolonged-release formulation confers a specialized mechanistic profile, maintaining a sustained concentration of Diclofenac within tissue reservoirs like the synovial fluid. This sustained presence at the primary site of pathology maintains continuous COX-2 inhibition, thereby modulating activity within the targeted pathways over an extended duration.

How to Use Inflamac retard

Inflamac retard, a prolonged-release (retard) tablet formulation of Diclofenac sodium, is administered according to standardized clinical principles. Its specialized design dictates its usage patterns, focusing on standardized dosing and adherence to administrative constraints.

---

Official Administration Guidelines

Usage Aspect	Guideline
Route & Form	Administered orally as an extended-release tablet.
Standard Dosing	The typical adult dose is 100 mg once daily. The total maximum daily dose of diclofenac should generally not exceed 150 mg across all forms.
Frequency	Taken once daily.
Intake Timing	May be administered with or after food. Intake may be timed for the evening to address morning symptoms.
Administration Method	The tablet must be swallowed whole with liquid and must not be crushed, broken, or chewed.

---

Use Protocol and Duration Principles

The fundamental principle for the use of this medicine is to employ the lowest effective dosage for the shortest duration necessary to achieve the desired effect. This measure guides the overall treatment protocol.

Population-Specific Guidance: For older adults, instructions require using the lowest effective dosage for the shortest possible duration, reflecting a cautious approach. The prolonged-release form is not recommended for the pediatric population. For patients with mild to moderate renal impairment, no specific dose adjustment is typically required.

These instructions collectively establish the required procedural steps and boundaries for using the prolonged-release Diclofenac formulation.

Research Evidence / Overview of Studies for Inflamac Retard

Evidence for Use in Osteoarthritis (OA)

Research exploring the use of this medication in conditions marked by functional limitations, such as osteoarthritis, primarily relies on short-term Randomized Controlled Trials (RCTs). These studies were designed to assess the patterns of symptoms measured during the study period. Studies generally focused on measuring outcomes related to physical discomfort, including patient-reported pain intensity, joint stiffness, and outcomes reflecting daily functioning or activity level in adults with confirmed OA. Studies monitored patient experiences over defined time intervals. Research provides insight into short-term changes observed in patients experiencing phases of heightened symptom activity.

Evidence for Use in Rheumatoid Arthritis (RA)

The medication was evaluated in controlled studies which explored patient-reported experiences related to joint pain and swelling. The research was observed in adult populations diagnosed with RA, often alongside patients receiving standard treatments. Studies monitored outcomes linked to inflammatory or irritative states and changes in global disease activity. A key limitation is that evidence quality varies across studies, and research indicates a primary focus on symptomatic changes. The research does not determine whether an individual will respond similarly, and data for certain subgroups remain insufficient for specific disease stages.

What Remains Uncertain or Under-Researched

Existing research provides context but also highlights several areas where data are still emerging or where certainty remains low. A significant gap is the lack of robust, consistent evidence demonstrating the drug’s potential to alter the structural progression of chronic conditions like OA or RA. Long-term effects are not fully established, especially concerning the durability of any observed changes in symptoms over many years of continuous use. Findings were mixed regarding the long-term impact on radiographic changes in conditions like ankylosing spondylitis, indicating that the research is ongoing. Comparative evidence is lacking in some areas, and follow-up durations were limited in many pivotal trials.

Key Studies & References Osteoarthritis in over 16s: diagnosis and management (NICE guideline NG226)

Common questions about Inflamac retard (FAQ)

---

Q: Can I take this medication if I am pregnant or breastfeeding?

Official product information contains a section detailing the use of this medicine during pregnancy and breastfeeding. This section outlines known risks, available human or animal data, and specific warnings. It is important to review the official product information and discuss your specific health needs with a qualified healthcare professional.

---

Q: Does this medicine contain a high amount of sodium, potassium, or sugar?

The ingredients of the medicine are listed in the official product documents, including inactive ingredients (excipients). If specific substances like sodium, potassium, or sugar derivatives are present in amounts that may be relevant to certain diets or conditions, this detail will be explicitly noted in the document.

---

Q: What should I do if I forget to take a dose?

Instructions for missed doses are clearly addressed in the approved patient labeling for Inflamac retard. This guidance provides specific directions, such as whether to take the dose as soon as you remember, skip it, or adjust your schedule. The patient information leaflet provides guidance, and you may also discuss the specific recommended action with a healthcare provider.

---

Q: Can I drink alcohol while taking this medicine?

Official regulatory warnings address the consumption of alcohol while using this medication. The product information will state if there is a known interaction, or if alcohol should be avoided entirely due to the potential for increased side effects or reduced effectiveness. Review the patient information leaflet for specific guidance regarding alcohol consumption.

---

Q: Does this medicine make you sleepy or affect my ability to drive?

Regulatory documents list potential side effects affecting the central nervous system, such as somnolence (sleepiness) or dizziness. The official product information also includes explicit warnings regarding the medicine’s potential to impair your ability to drive or safely operate machinery. Patients are advised to review the patient information leaflet if they experience these effects.

---

Q: Can children 2 years old use this medicine?

The official labeling specifies the approved population for the use of this medicine, including any minimum age or weight restrictions. If the age of 2 years falls outside of the established use, the documentation will state the age group for which the medicine's safety and effectiveness have been confirmed.

---

Q: Can I take this for migraines?

The official labeling lists the specific medical conditions or diseases for which Inflamac retard has been formally approved, known as therapeutic indications. The medicine is approved only for the conditions explicitly stated in this section of the regulatory document. Information on use for conditions not listed, like migraines, is not included in the official approval.

How to Store and Dispose of Inflamac Retard: Official Requirements

The storage and disposal instructions for Inflamac Retard are defined by regulatory documents to maintain the medicine's quality and ensure public safety.

---

Storage Conditions

• Temperature: The product must be stored below 30°C.
• Protection: The medicine must be protected from moisture and kept in the original blister pack to maintain stability.
• Child Safety: Inflamac Retard must be kept out of the sight and reach of children.

---

Disposal Instructions

• Restriction: The medicine must not be disposed of via wastewater or household waste.
• Procedure: Unused or expired product should be disposed of in accordance with local regulatory requirements, typically through a pharmacy take-back program.